Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in severe mast cell activation syndrome
2021-005406-96Phase 2Terminated
- Sponsor
- AB Science
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mast Cell Activation Syndrome (MCAS) comparing Masitinib with Placebo (2 arms). Primary endpoint: Confirmed response at 50% at week 24 on 3 handicap scores. Started Jun 2022; status: terminated.
02
Drugs
masitinib
03
Conditions
Mast Cell Activation Syndrome (MCAS)
Beyond the preview
Go deeper on 2021-005406-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005406-96.